Premium
Delhi-based biopharmaceutical firm Vyome Biosciences Pvt Ltd said it will start clinical trials for its flagship acne product in the US in the next quarter.The product, christened VB1953, is targeted at antibiotic-resistant acne and has a global market potential of $4 billion, Vyome Biosciences CEO N Venkat said.Venkat, who previously ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
